Long-Versus Short-Term Seizure Prophylaxis After Craniotomy for Clipping in Aneurysmal Subarachnoid Hemorrhage; A Retrospective Cohort Study

Abdolkarim Rahmanian¹, Alireza Mohsenian Sisakht¹,², Nima Derakhshan¹,³, Najme Karamzade Ziarati³, Seyed Hossein Owji⁴ and Hadi Raeisi Shahraki⁵

¹Department of Neurosurgery, Shiraz University of Medical Sciences, Shiraz, Iran
²Research Committee, Iran University of Medical Sciences, Tehran, Iran
³Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran
⁴Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
⁵Department of Epidemiology and Biostatistics, Faculty of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran

Corresponding author: Department of Neurosurgery, Shiraz University of Medical Sciences, Shiraz, Iran. Email: nderakhshan26@gmail.com

Received 2018 February 27; Revised 2018 December 02; Accepted 2019 February 13.

Abstract

Background: Seizures are quite common following subarachnoid hemorrhage (SAH) and due to increased mortality and morbidity in this setting, thus seizure prophylaxis is introduced as a common neurosurgical practice. Investigations are still ongoing to figure out the most efficient seizure prophylaxis guideline.

Objectives: To compare the efficacy of two seizures prophylaxis protocols that have been practiced in a tertiary neurovascular center in Southern Iran through a retrospective cohort analysis

Methods: A total of 426 patients who were operated due to aneurysmal SAH between September 2007 and March 2016 were included in this retrospective cohort study. From September 2007 to March 2011 the common practice was prophylaxis with phenytoin for 3-6 months, which was switched to a shorter 1-month course since March 2011. Seizure control was evaluated in telephoned patients and outpatient records.

Results: Out of 426 subjects eligible for this study, 165 (38.7%) took the 1-month (short-term) regimen and 261 (61.3%) took the 3-6 months (long-term) regimen. Results revealed that achievement of seizure control was similar for both groups in those without perioperative seizures (P = 0.4); however, with perioperative seizures, the short-term protocol had inferior results for seizure control and higher odds (almost 109-fold) for developing post-operative seizures.

Conclusions: Although short-term 1-month seizure prophylaxis with phenytoin provides adequate seizure control for most individuals after SAH, perioperative seizures necessitates a longer course of 3-6 month seizure prophylaxis.

Keywords: Cerebral Aneurysm, Seizure Prophylaxis, Clipping, SAH, Phenytoin

1. Background

Seizures are common after subarachnoid hemorrhage (SAH) (1) and are believed to negatively affect the quality of life of these patients and even increase their mortality rate (2). The incidence of seizures following SAH is variable according to different reports. However, between 6% and 24% of SAHs are complicated by seizures, making seizure prophylaxis a common practice in neuro-critical and neuro-rehabilitation care of such patients (2-4). In international subarachnoid aneurysm trial (ISAT) out of 235 patients, 10.9% developed with different types of seizures, including secondarily generalized seizures, partial seizures, “blackouts”, nocturnal seizures, and seizure of unknown type (5).

Seizure following SAH may occur by either direct injury from blood or blood products in the subarachnoid space or through ischemic complications of vasospasm (6). Early clinical seizures are found to be associated with the volume of blood in the subarachnoid space (Fisher grade) (6) and damage to the motor or insular cortices (7), the combined effects of a space-occupying lesion with mass effect, focal ischemia, blood products catalyzing neuroexcitotoxic damage through glutamate release, and generation of free radicals (8, 9). Various seizure prophylaxis protocols have been practiced utilizing different anti-epileptic drugs (AEDs) for variable durations, but a consensus for a standard regimen is yet to be developed.
Different institutions have suggested the use of AEDs for one week to 1 year following SAH, administering phenytoin, sodium valproate (3, 10), levetiracetam carbamazepine, and other AEDs with certain adjustments based on patients’ risk factors and side effect profile of drugs.

2. Objectives

Therefore, we used two different protocols in separate time frames for seizure prophylaxis in SAH patients at our institution. Subsequently, we compared the two regimens and clarified the optimal regimen for patients with certain risk factors.

3. Methods

3.1. Study Population

A total of 474 patients with aneurysmal SAH who underwent clipping in Shiraz Namazi Hospital (the main referral neurovascular center of Southern Iran) (11-14) were included in this cohort study from September 2007 to March 2016. Those with incomplete hospital and outpatient records were excluded. Thus a total of 426 patients were eligible to enter the study.

3.2. Data Collection

Patients’ data, including demographics and a previous history of seizure, was obtained from hospital records. Hospital progress notes and ICU sheets were investigated to look for in-patient seizures. To record the frequency of seizures and functional outcome after the discharge of the patient, out-patient records and telephone calls were utilized.

3.3. Treatment Protocols

Since the development of neuro-vascular unit in September 2007 as a subspecialty at our department, the routine practice for seizure prophylaxis was 1000 mg intravenous (IV) phenytoin in a stat dose, followed by 300 mg daily IV phenytoin in three divided doses, which was switched to oral, as soon as the feeding was started for the patients. Patients who developed allergic reactions to phenytoin were excluded from this survey.

During the first 4 years (September 2007 till March 2011) we continued the phenytoin administration for 3 months and tapered it over the next 3 months (protocol A). But afterward till March 2016 following the emergence of several papers, which proposed shorter-course-protocols for seizure prophylaxis after SAH with the same results for seizure control (15-17), patients were subjected to continue the prophylaxis for 1 month followed by tapering in 2 weeks (protocol B).

Those who were known cases of seizure and took medication were also excluded, but those whose seizures were controlled without medication were also enrolled in this survey. The flow chart of patients’ distribution in the two protocols was summarized in Figure 1.

3.4. Glossary

The perioperative seizure was referred to as repetitive and rhythmic jerky movements with or without preceding tonic phase and with or without alterations in consciousness within 1 month prior to admission until the discharge of the patient from the hospital. Both focal and generalized seizures were taken into account. Late seizures were defined as seizures, which occurred after the discharge of the patient. In-hospital seizures were recorded by medical staff and late seizures by family members and caregivers.

3.5. Statistical Analysis

The two groups were compared by the Pearson chi-square test and independent t-test to compare demographic characteristics, mean GCS, H&H grade, and comorbidities. Multivariate logistic regression analysis was utilized to investigate the simultaneous effect of variables on post-operative seizure frequency. All the statistical analyses were performed using statistical package for social sciences (SPSS Inc., Chicago, Illinois, USA) version 22.0 and a P value less than 0.05 was considered statistically significant.

4. Results

Out of the patients who met the criteria to be included in this survey, 165 (38.7%) took protocol A (long-term) and 261 (61.3%) took protocol B (short-term) as seizure prophylaxis following SAH. There was no significant difference between both genders (51.2% female and 48.8% male) and most patients were aged between 40 and 60 years in the studied population.

Using the Pearson chi-square test, we found out that the two groups did not vary according to sex distribution, but the patients who took protocol A were significantly older than those taking protocol B (P = 0.018). Also, the proportion of subjects with a known previous history of seizure was significantly higher in protocol B (8.8% versus 3%, P = 0.019) (Table 1). The two groups did not significantly vary according to primary GCS, H&H grade, and comorbidities (meningitis, hydrocephalus, and delayed ischemia) (P > 0.05).
Total patients who underwent surgical Clipping for Aneurysmal SAH between September 2008 and March 2016 (N = 474)

48 patients were excluded due to allergy to phenytoin, Previous history of epilepsy, incomplete hospital or outpatient records and unavailability for follow-up

A total of 426 patients were found eligible to enter the analysis

Patients operated between September 2007 and March 2011 who received Phenytoin 300mg QD for 3 month which was then tapered to D/C over next 3 months (Protocol A) N = 165

Patients operated between April 2011 and March 2016 who received Phenytoin 300mg QD for 1 month which was then tapered to D/C over two weeks (Protocol B) N = 216

Incidence of Late-onset seizures were compared between these two protocols

Patients without perioperative seizures (160 in protocol A and 238 in protocol B) did not show any difference in terms of late seizures. (3.8% in both groups; P value = 0.99) However, in patients with perioperative seizures, late seizures were significantly higher in those taking the short-term protocol (91.3% versus 40% in protocols B and A, respectively; P = 0.027) (Table 2). After matching the age and sex within the two groups, multivariate logistic regression analysis revealed that the short-term prophylaxis protocol (B) was not associated with higher late seizures (P = 0.40, CI: 95% and OR = 1.54). However, a record of perioperative seizures significantly increased the odds of late seizures (P < 0.001, CI: 95% and OR = 109.41) (Table 3).

Figure 1. Flowchart of dividing the patients within the two protocols
Table 1. Demographic Characteristics and Perioperative Seizures of the Two Groups

| Variables | Protocol A (%) | Protocol B (%) | P Value |
|-----------|----------------|----------------|---------|
| Sex       |                |                | 0.28    |
| Male      | 75 (45.5)      | 133 (51.0)     |         |
| Female    | 90 (54.5)      | 128 (49.0)     |         |
| Age       |                |                | 0.018   |
| < 20      | 6 (3.6)        | 10 (3.8)       |         |
| 20-40     | 24 (14.5)      | 66 (25.3)      |         |
| 40-60     | 83 (50.3)      | 133 (51.0)     |         |
| 60-70     | 37 (22.4)      | 41 (15.7)      |         |
| > 70      | 15 (9.1)       | 11 (4.2)       |         |
| Mean Age  |                |                |         |
| Male      | 49.3 ± 3.6     | 47.3 ± 4.1     | 0.31    |
| Female    | 50.1 ± 4.2     | 49.2 ± 4.2     | 0.14    |
| Perioperative seizures | | | 0.019 |
| No        | 160 (97.0)     | 238 (91.2)     |         |
| Yes       | 5 (3.0)        | 23 (8.8)       |         |

Table 2. Comparison of Long (A) and Short (B)-Term Protocols of Seizure Prophylaxis According to Perioperative Seizures

| Perioperative Seizures | Late Seizures | P Value |
|------------------------|---------------|---------|
|                        | No (%)        | Yes (%) |
| No                     | 154 (96.2)    | 6 (3.8) |
| Protocol A             | 229 (96.2)    | 9 (3.8) |
| Total                  | 383           | 15      |
| Yes                    |               |         |
| Protocol A             | 3 (60.0)      | 2 (40.0) |
| Protocol B             | 2 (8.7)       | 21 (91.3) |
| Total                  | 5             | 23      |

5. Discussion

Seizures are frequent following SAH and tend to negatively impact the functional outcome and quality of life of patients with SAH. Several factors have been suggested to increase the risk of early seizures in the setting of SAH, such as younger age (1, 3, 18, 19), clinical grade (in terms of Glasgow coma scale and Hunt and Hess grade) (20, 21), hypertension (22), presence of hydrocephalus (3, 23), the need for a CSF shunting procedure (23, 24), re-bleeding before surgical obliteration of aneurysm (24), previous history of seizures, intra-ventricular and intraparenchymal hemorrhage, as well as thickness of blood clot on computed tomography (CT) scans in terms of Fisher and modified Fisher grade. For the late seizures to develop following SAH, cortical infarctions and higher Fisher grades were suggested as the most common underlying causes.

Despite recent efforts to introduce a guideline for seizure prophylaxis in SAH patients, a consensus regarding a uniform protocol for all of these patients has not been achieved. Several authors have questioned the benefits of seizure prophylaxis for all patients and many others believe that they can only prevent late seizures in patients with certain risk factors (3, 25). Different seizure prophylaxis regimens are used in neuro-vascular units, primarily based on experience with certain medication and the dosage and duration of prophylaxis are determined according to patients’ drug history, past medical history of central nervous system lesions, the occurrence of seizures, drug interactions, and side effect profile.

Despite several flaws, historical cohorts still remain reliable sources of evidence when prospective studies are imperfect. Therefore, we provided a retrospective cohort analysis comparing two treatment protocols, which were practiced in recent years in our neurovascular center. According to this survey, we believe that a short-term 1-month administration of phenytoin provides adequate seizure prophylaxis, confirming that the continuation of prophylaxis beyond this time is unnecessary. However, patients with perioperative seizures tend to experience a higher rate of late seizures if the medication is discontinued early within one month.

Our results are congruent with the proponents of shorter duration of seizure prophylaxis, as it avoids the unnecessary resumption of AEDs for patients with a standard-risk profile. However, unlike many others who do not see a perioperative seizures history to recur after SAH, we believe that this factor necessitates a longer duration of AED continuance. Choi et al. found the AEDs are useless in preventing early seizures and they introduced surgery-induced cortical damage and initial thickness of blood as important factors for considering prophylaxis against late seizures after SAH. However, they did not find perioperative seizures to be a predictor of late-onset seizures (3). We disagree with this finding as in our series, late seizures had a tendency to develop more frequently in those with perioperative seizures who received short-term prophylaxis.

Altogether, this study was accompanied by certain limitations of retrospective cohort studies such as selection bias, missed data, non-homogeneity of cases, uncertainty about the drug dosages administered and the quality of therapeutics (such as different brands of the same medication). These limitations concern the researchers and necessitate prudent analysis of the results. Another limitation of this study is that non-convulsive seizures (21) were not included because routine EEG monitoring in the hospital
was not the standard practice at our center at the time this cohort was evaluated.

5.1. Future Perspective

Because drug interactions are commonly seen with phenytoin and its negative impact on functional and cognitive outcome (26), the recent trend is to continue a shorter duration with safer AEDs available in the market such as levetiracetam. Levetiracetam is also believed to improve cognitive and functional outcome after SAH (27). In a systematic review by Lanzino et al., a 3-day seizure prophylaxis regimen was found to provide sufficient control for post-operative seizures, and they related the worse outcome associated with AEDs to phenytoin (28). Other recent studies also emphasize brief courses of 3 to 7 days of prophylaxis and save the extended prophylaxis for those with mentioned risk factors (14, 29). From March 2016, we have switched to a 1-week course of phenytoin or levetiracetam and the results were promising so far for seizure control (13). The results of an ongoing prospective clinical trial at our center will provide further evidence for guidelines of seizure prophylaxis in SAH patients.

5.2. Recommendations

The most recent recommendations applied by many academic centers for seizure prophylaxis in SAH are as follow (30):

- Prophylaxis should be initiated in patients under the following conditions
  1. Hunt & Hess grade 4 or 5,
  2. Fisher grade III or IV,
  3. Modified Fisher grade II-IV,
  4. Concomitant intracerebral hemorrhage,
  5. MCA aneurysm,
  6. History of hypertension.
- AED
  1. Levetiracetam,
    a. Good adverse effect profile,
    b. No therapeutic drug monitoring required,
    c. Correlated to beneficial outcomes.
  2. Dosing
    a. Loading: 20 mg/kg IV infusion,
    b. Maintenance: 10 mg/kg twice daily IV or enteral.
- Duration
  1. Initiate immediately upon diagnosis or strong suspicion of SAH,
  2. The total duration of 8 days,
  3. Consider prolonged duration if a seizure occurs during the hospital stay.

5.3. Conclusions

Although short-term 1-month prophylaxis with phenytoin provides efficient seizure control following SAH, a history of perioperative seizures necessitates a longer course of seizure prophylaxis.

Footnotes

Authors' Contribution: Abdolkarim Rahmanian was the chief surgeon and contributed in initial design. Alireza Mohsenian Sisakht designed the methodology of this work. Nima Derakhshan contributed to the writing of manuscript and critical review of the revised version. Najme Karamzade Ziarati and Seyed Hossein Owji contributed to data gathering from patients’ files. Hadi Reisi Shahraki completed the statistical analysis.

Conflict of Interests: There is no financial conflict of interest in relation to this article.

Ethical Approval: The treatment protocols mentioned in the method section were reviewed and approved by the Institutional Review Board Members of Ethical Committee at the vice chancellor for research of Shiraz University of Medical Sciences (http://research.sums.ac.ir/fa/ethicrc/EthicsCodes.html).

Funding/Support: None of the authors have received any funding regarding this work.

References

1. Claassen J, Peery S, Kreiter KT, Hirsch LJ, Du EY, Connolly ES, et al. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology. 2003;60(2):208-14. [PubMed: 12352032].
2. Butzkueven H, Evans AH, Pitman A, Leopold C, Jolley DJ, Kaye AH, et al. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. Neurology. 2006;66(9):1315-20. [PubMed: 1687774].
10. Mink S, Muroi C, Seule M, Bjeljac M, Keller E. Levetiracetam compared with phenytoin for the prevention of seizures after subarachnoid hemorrhage: a randomized controlled trial. J Neurosurg. 2019;6(2):e68108. [PubMed Central: PMC744302].

11. Rahmanian A, Jamali M, Razmkon A, Kivelev J, Romani R, Alibai EA, et al. Benefits of early aneurysm surgery: Southern Iran experience. World J Surg. 2018;42(10):2548-65. doi: 10.1007/s00268-018-4683-5. [PubMed: 30033896].

12. Lee WL, Hablitz JJ. Initiation of epileptiform activity by excitatory amino acid receptors in the disinhibited rat neocortex. J Neurophysiol. 1991;65(3):87-95. doi: 10.1152/jn.1991.65.1.87. [PubMed: 167877].

13. Rahmanian A, Derakhshan N, Mohsenian Sisakht A, Karamzadeh P, Crago E, et al. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology. 2005;65(2):254-65. doi: 10.1212/01.wnl.0000183033.62204.69. [PubMed: 16098901].

14. Rahmanian A, Sisakht A, Derakhshan N, Ziarati N, Shahraki H, Nati M, et al. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology. 2005;65(2):254-65. doi: 10.1212/01.wnl.0000183033.62204.69. [PubMed: 16098901].

15. Lin CL, Dumont AS, Lieu AS, Yen CP, Hwang SL, Kwan AL, et al. Characteristics of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(6):978-85. doi: 10.3171/jns.2003.99.6.0978. [PubMed: 14705724].

16. Bidzinski J, Marchel A, Sheriff A. Risk of epilepsy after aneurysm operation. Acta Neurochir [Wien]. 1992;119(1-4):49-52. [PubMed: 14875752].

17. Murphy-Human T, Welch E, Zipfel G, Diringer MN, Dhar R. Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage. World Neurosurg. 2011;75(2):259-74. doi: 10.1016/j.wneu.2010.09.002. [PubMed: 21492729].

18. Lin CL, Dumont AS, Lieu AS, Yen CP, Hwang SL, Kwan AL, et al. Characteristics of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(6):978-85. doi: 10.3171/jns.2003.99.6.0978. [PubMed: 14705724].

19. Bidzinski J, Marchel A, Sheriff A. Risk of epilepsy after aneurysm operation. Acta Neurochir [Wien]. 1992;119(1-4):49-52. [PubMed: 14875752].

20. Rhoney DH, Tipps LB, Murry KR, Basham MC, Michael DB, Coplin WM. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology. 2005;65(2):254-65. doi: 10.1212/01.wnl.0000183033.62204.69. [PubMed: 16098901].

21. Dennis LJ, Claassen J, Hirsch LJ, Emerson RG, Connolly ES, Mayer SA. Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1336-43. discussion 144. [PubMed: 12383158].

22. Ohman J, Hypertension as a risk factor for epilepsy after aneurysmal subarachnoid hemorrhage and surgery. Neurosurgery. 1990;27(4):578-81. [PubMed: 2234361].

23. Jaja BNR, Schweizer TA, Claassen J, Le Roux P, Mayer SA, Macdonald RL, et al. The SAFARI score to assess the risk of convulsive seizure during admission for aneurysmal subarachnoid hemorrhage. Neurosurgery. 2018;82(6):887-93. doi: 10.1093/neuros/nyx334. [PubMed: 28971369].

24. Hart RG, Byer JA, Slaughter JR, Hewett JE, Easton JD. Occurrence and implications of seizures in subarachnoid hemorrhage due to ruptured intracranial aneurysms. Neurosurgery. 1981;18(4):447-21. [PubMed: 7242892].

25. Panczykowski D, Pease M, Zhao Y, Weiner G, Ares W, Crago E, et al. Prophylactic antiepileptics and seizure incidence following subarachnoid hemorrhage: A propensity score-matched analysis. Stroke. 2015;47(7):1754-60. doi: 10.1161/STR.0000000000000366. [PubMed: 2730932]. [PubMed Central: PMC4927347].

26. Naidech AM, Kreiter KT, Janjua N, Ostapkovich N, Parra A, Comichau C, et al. Phenytoin exposure is associated with functional outcome of seizures after aneurysm occlusion or coil embolization of a ruptured cerebral aneurysm: Results from the International Subarachnoid Aneurysm Trial. J Neurosurg. 2013;119(5):1711-37. doi: 10.3171/jns.2013.119.5.0606. [PubMed: 24474161].

27. Taylor S, Heinrichs RJ, Janjua N, Ostapkovich N, Parra A, Comichau C, et al. Phenytoin exposure is associated with functional outcome of seizures after aneurysm occlusion or coil embolization of a ruptured cerebral aneurysm: Results from the International Subarachnoid Aneurysm Trial. J Neurosurg. 2013;119(5):1711-37. doi: 10.3171/jns.2013.119.5.0606. [PubMed: 24474161].

28. [PubMed Central: PMC5823718].

29. Lanzino G, D’Urso PI, Suarez J; Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15(1):60-4. doi: 10.1007/s12028-010-9341-6. [PubMed: 20890680].

30. Taylor S, Heinrichs RJ, Janjua N, Ostapkovich N, Parra A, Comichau C, et al. Phenytoin exposure is associated with functional outcome of seizures after aneurysm occlusion or coil embolization of a ruptured cerebral aneurysm: Results from the International Subarachnoid Aneurysm Trial. J Neurosurg. 2013;119(5):1711-37. doi: 10.3171/jns.2013.119.5.0606. [PubMed: 24474161].

31. Human T, Diringer MN, Allen M, Zipfel GJ, Chicoine M, Dacey R, et al. A randomized trial of brief versus extended seizure prophylaxis after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2018;28(2):169-74. doi: 10.1007/s12028-017-0440-5. [PubMed: 2883777]. [PubMed Central: PMC5823718].

32. Boeck DG. Seizure prophylaxis in aneurysmal subarachnoid hemorrhage: Should we shake it off? Pamphlet of Pharmacotherapy Education and Research Center, University of Texas Health Science Center at San Antonio; 2015.